Qiagen Acquires Molecular Staging Assets

Qiagen said this week that it has acquired technology assets from Molecular Staging, including the company’s whole-genome amplification and rolling-circle amplification technologies, for $28.5 million.

Under the terms of the agreement, Qiagen purchased the technology assets of MSI, including more than 160 applied or issued patents, for $28.5 million in cash plus potential earn-outs of up to $6.75 million.